International Journal of Hematology

, Volume 96, Issue 6, pp 743–747

Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy

Authors

  • Brian McLaughlin
    • Division of Hematology and Oncology, University of Pittsburgh Cancer InstituteUniversity of Pittsburgh School of Medicine
  • Annie Im
    • Division of Hematology and Oncology, University of Pittsburgh Cancer InstituteUniversity of Pittsburgh School of Medicine
  • Anastasios Raptis
    • Division of Hematology and Oncology, University of Pittsburgh Cancer InstituteUniversity of Pittsburgh School of Medicine
  • Mounzer Agha
    • Division of Hematology and Oncology, University of Pittsburgh Cancer InstituteUniversity of Pittsburgh School of Medicine
  • Jing-Zhou Hou
    • Division of Hematology and Oncology, University of Pittsburgh Cancer InstituteUniversity of Pittsburgh School of Medicine
  • Robert Redner
    • Division of Hematology and Oncology, University of Pittsburgh Cancer InstituteUniversity of Pittsburgh School of Medicine
  • Shrina Duggal
    • Division of Hematology and Oncology, University of Pittsburgh Cancer InstituteUniversity of Pittsburgh School of Medicine
  • Yan Lin
    • Division of Hematology and Oncology, University of Pittsburgh Cancer InstituteUniversity of Pittsburgh School of Medicine
  • Clay Smith
    • Division of Hematology and Oncology, University of Pittsburgh Cancer InstituteUniversity of Pittsburgh School of Medicine
    • Division of Hematology and Oncology, University of Pittsburgh Cancer InstituteUniversity of Pittsburgh School of Medicine
Original Article

DOI: 10.1007/s12185-012-1192-9

Cite this article as:
McLaughlin, B., Im, A., Raptis, A. et al. Int J Hematol (2012) 96: 743. doi:10.1007/s12185-012-1192-9

Abstract

The most effective regimen for relapsed acute myeloid leukemia (AML) patients who do not achieve complete remission (CR) after a course of salvage therapy has not been established. We evaluated the efficacy and toxicity of fludarabine and cytarabine in patients with AML in first relapse who did not respond to a course of salvage chemotherapy with mitoxantrone and etoposide. CR was achieved in 39 % of treated patients, and in 47 % of patients with a favorable/intermediate-risk karyotype. The median overall survival was 4.75 months. The median survival for patients achieving CR with fludarabine–cytarabine was significantly higher than for those who did not respond to therapy (9.6 vs. 4.5 months, P = 0.04). Our data suggest that the fludarabine–cytarabine regimen merits further investigation in relapsed AML patients with favorable or intermediate-risk karyotype with persistent leukemia after a course of salvage therapy.

Keywords

Acute myeloid leukemiaRelapse leukemiaFludarabineCytarabine

Copyright information

© The Japanese Society of Hematology 2012